Rocket Pharmaceuticals (RCKT) Takes A Major Step Forward with the Danon Clinical Hold Being Lifted - BofA Securities
Tweet Send to a Friend
BofA Securities analyst Greg Harrison reiterated a Buy rating and $70.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
